EGFR and non-small cell lung carcinoma: Activating mutations in the epidermal growth factor receptor (EGFR) gene in non-small-cell lung cancer (NSCLC) lead to an increase in growth factor signaling activity and susceptibility to tyrosine kinase inhibitors (TKIs) [1, 2].